{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:45:36Z","timestamp":1794872736724,"version":"4.9.1"},"reference-count":60,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is an urgent need to find more effective treatments for motor and non-motor symptoms of Parkinson's disease (PD) and to ultimately discover therapies to slow, stop or reverse the condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide an overview of PD drug therapies in Phase 1\u20133 clinical trials between 2015\u20132024 in order to highlight research findings and trends, identify opportunities for further research and funding, and provide a common ground for discussion among the patient, research and funding communities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A dataset of PD drug clinical trials registered on ClinicalTrials.gov between 2015\u20132024 was analyzed and classified by trial focus (symptomatic therapy or disease-modifying therapy), trial phase, therapeutic category and drug novelty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The dataset included 444 trials, of which 42% were in Phase 1, 46% in Phase 2 and 12% in Phase 3. 63% of the trials were evaluating symptomatic therapies (ST) and 37% were testing disease-modifying therapies (DMT). 52% of the trials were exploring novel treatments, a third were testing repurposed compounds and the remainder were evaluating reformulations of existing PD drugs. 281 drug interventions were evaluated across the 444 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pipeline of clinical trials evaluating PD drug therapies between 2015\u20132024 contained a diverse set of novel, repurposed and reformulated compounds across a variety of biological pathways. While additional symptomatic treatments received regulatory approval, there are still no treatments to modify the course of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x261454154","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:44:47Z","timestamp":1779799487000},"page":"1362-1376","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Parkinson's disease drug therapies in the clinical trial pipeline: 2015\u20132024"],"prefix":"10.1177","volume":"16","author":[{"given":"Susan","family":"Buff","sequence":"first","affiliation":[{"name":"Parkinson's research advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pilcicka","sequence":"additional","affiliation":[{"name":"Cure Parkinson's"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Pitzer","sequence":"additional","affiliation":[{"name":"Parkinson's research advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8797-2042","authenticated-orcid":false,"given":"Brian","family":"Fiske","sequence":"additional","affiliation":[{"name":"The Michael J Fox Foundation for Parkinson's Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4664","authenticated-orcid":false,"given":"Simon RW","family":"Stott","sequence":"additional","affiliation":[{"name":"Cure Parkinson's"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1051-1143","authenticated-orcid":false,"given":"Kevin","family":"McFarthing","sequence":"additional","affiliation":[{"name":"Parkinson's research advocate, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2401857"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.09.004"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22028"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1449973"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00305-9"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202128"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-219006"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-229002"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-239901"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240272"},{"key":"e_1_3_4_12_2","unstructured":"About ClinicalTrials.gov | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/about-site\/about-ctg (accessed 26 February 2026)."},{"key":"e_1_3_4_13_2","unstructured":"Glossary Terms | ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study-basics\/glossary (accessed 16 December 2025)."},{"key":"e_1_3_4_14_2","unstructured":"Clinical Trials Registration and Results Information Submission. Federal Register https:\/\/www.federalregister.gov\/documents\/2016\/09\/21\/2016-22129\/clinical-trials-registration-and-results-information-submission (2016 accessed 26 February 2026)."},{"key":"e_1_3_4_15_2","unstructured":"AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson\u2019s Disease. AbbVie News Center https:\/\/news.abbvie.com\/2025-09-26-AbbVie-Submits-New-Drug-Application-to-U-S-FDA-for-Tavapadon-for-the-Treatment-of-Parkinsons-Disease (accessed 16 December 2025)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012868"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0257-7"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08845-y"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08700-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072366"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0066-7"},{"key":"e_1_3_4_22_2","unstructured":"Nouryant | European Medicines Agency (EMA) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nouryant (2021 accessed 15 January 2026)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2022.01.032"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202058"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202867"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02886-y"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03270-6"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203395"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.124.002199"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf304"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2658"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29297"},{"key":"e_1_3_4_33_2","unstructured":"Neuron 23. Neuron23. Neuron23 https:\/\/neuron23.com\/neuron23-to-present-phase-1-healthy-volunteer-data-of-neu-411-a-brain-penetrant-lrrk2-inhibitor-at-ad-pd-2025\/ (2025 accessed 16 January 2026)."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4611"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29346"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136094"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203618"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202435"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1575"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29450"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.11.022"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251356503"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30190"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20737"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.134"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz023"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X241301041"},{"key":"e_1_3_4_48_2","unstructured":"Patient Resources. International Society for Stem Cell Research https:\/\/www.isscr.org\/treatment-guide (accessed 16 January 2026)."},{"key":"e_1_3_4_49_2","unstructured":"3. Clinical Translation of Stem Cell-based Interventions. International Society for Stem Cell Research https:\/\/www.isscr.org\/guidelines\/clinical-translation-of-stem-cell-based-interventions (accessed 16 January 2026)."},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-025-01029-3"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02808-3"},{"key":"e_1_3_4_53_2","unstructured":"News Details. Novo Nordisk https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html (accessed 16 January 2026)."},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01154-1"},{"key":"e_1_3_4_55_2","unstructured":"Freeman K. Research Community. Aligning Science Across Parkinson\u2019s https:\/\/parkinsonsroadmap.org\/research-community-overview\/ (accessed 26 February 2026)."},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01039-3"},{"key":"e_1_3_4_57_2","unstructured":"Australian Parkinson\u2019s Mission | Garvan Institute of Medical Research https:\/\/www.garvan.org.au\/research\/collaboration\/australian-parkinsons-mission (accessed 26 February 2026)."},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad063"},{"key":"e_1_3_4_59_2","unstructured":"Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale France. Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort). Clinical Trial Registration NCT04888364 clinicaltrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04888364 (10 January 2025 accessed 23 March 2026)."},{"key":"e_1_3_4_60_2","unstructured":"NS-PARK launches Master Trial France\u2019s first clinical trial platform to accelerate the identification of neuroprotective treatments for Parkinson\u2019s disease | F-CRIN https:\/\/www.fcrin.org\/en\/media\/press\/ns-park-launches-master-trial-frances-first-clinical-trial-platform-accelerate (accessed 23 March 2026)."},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100645"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261454154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X261454154","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261454154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:33Z","timestamp":1793943993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X261454154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/1877718X261454154"],"URL":"https:\/\/doi.org\/10.1177\/1877718x261454154","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}